These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

508 related articles for article (PubMed ID: 24145678)

  • 21. Effect of Iron Isomaltoside on Skeletal Muscle Energetics in Patients With Chronic Heart Failure and Iron Deficiency.
    Charles-Edwards G; Amaral N; Sleigh A; Ayis S; Catibog N; McDonagh T; Monaghan M; Amin-Youssef G; Kemp GJ; Shah AM; Okonko DO
    Circulation; 2019 May; 139(21):2386-2398. PubMed ID: 30776909
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Iron isomaltoside 1000: a new intravenous iron for treating iron deficiency in chronic kidney disease.
    Wikström B; Bhandari S; Barany P; Kalra PA; Ladefoged S; Wilske J; Thomsen LL
    J Nephrol; 2011; 24(5):589-96. PubMed ID: 21240875
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Prospective Randomised Controlled Trial of a Single Intravenous Infusion of Ferric Carboxymaltose vs Single Intravenous Iron Polymaltose or Daily Oral Ferrous Sulphate in the Treatment of Iron Deficiency Anaemia in Pregnancy.
    Khalafallah AA; Hyppa A; Chuang A; Hanna F; Wilson E; Kwok C; Yan C; Gray Z; Mathew R; Falloon P; Dennis A; Pavlov T; Allen JC
    Semin Hematol; 2018 Oct; 55(4):223-234. PubMed ID: 30502851
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of iron deficiency in patients with chronic kidney disease: A prospective observational study of iron isomaltoside (NIMO Scandinavia)
.
    Jensen G; Gøransson LG; Fernström A; Furuland H; Christensen JH
    Clin Nephrol; 2019 Apr; 91(4):246-253. PubMed ID: 30614439
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of iron isomaltoside 1000 in patients with inflammatory bowel disease.
    Nordfjeld K; Andreasen H; Thomsen LL
    Drug Des Devel Ther; 2012; 6():43-51. PubMed ID: 22419860
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correction of Iron Deficiency Anemia With Intravenous Iron Sucrose in Children With Inflammatory Bowel Disease.
    Danko I; Weidkamp M
    J Pediatr Gastroenterol Nutr; 2016 Nov; 63(5):e107-e111. PubMed ID: 27540710
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intravenous iron for the treatment of iron deficiency in IBD: the pendulum is swinging.
    Van Assche G
    Am J Gastroenterol; 2013 Dec; 108(12):1889-90. PubMed ID: 24300864
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A systematic literature review and indirect comparison of iron isomaltoside and ferric carboxymaltose in iron deficiency anemia after failure or intolerance of oral iron treatment.
    Pollock RF; Muduma G
    Expert Rev Hematol; 2019 Feb; 12(2):129-136. PubMed ID: 30689458
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intravenous iron treatments for iron deficiency anemia in inflammatory bowel disease: a budget impact analysis of iron isomaltoside 1000 (Monofer) in the UK.
    Pollock RF; Muduma G
    Expert Opin Drug Deliv; 2017 Dec; 14(12):1439-1446. PubMed ID: 29032713
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Intravenous iron sucrose in maintenance dialysis patients with renal anemia: a clinical study].
    Li H; Wang SX
    Zhonghua Yi Xue Za Zhi; 2009 Feb; 89(7):457-62. PubMed ID: 19567093
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A prospective, multi-center, randomized comparison of iron isomaltoside 1000 versus iron sucrose in patients with iron deficiency anemia; the FERWON-IDA trial.
    Auerbach M; Henry D; Derman RJ; Achebe MM; Thomsen LL; Glaspy J
    Am J Hematol; 2019 Sep; 94(9):1007-1014. PubMed ID: 31243803
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized, controlled, open label non-inferiority trial of intravenous ferric carboxymaltose versus iron sucrose in patients with iron deficiency anemia in China.
    Jin J; Ran Z; Noseda E; Roubert B; Marty M; Mezzacasa A; Göring UM
    Front Med; 2024 Feb; 18(1):98-108. PubMed ID: 37897561
    [TBL] [Abstract][Full Text] [Related]  

  • 33. NIMO-CKD-UK: a real-world, observational study of iron isomaltoside in patients with iron deficiency anaemia and chronic kidney disease.
    Kalra PA; Bhandari S; Spyridon M; Davison R; Lawman S; Mikhail A; Reaich D; Pritchard N; McCafferty K; Moore J
    BMC Nephrol; 2020 Dec; 21(1):539. PubMed ID: 33302891
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pediatric Crohn's disease, iron deficiency anemia and intravenous iron treatment: a follow-up study.
    Valério de Azevedo S; Maltez C; Lopes AI
    Scand J Gastroenterol; 2017 Jan; 52(1):29-33. PubMed ID: 27576956
    [TBL] [Abstract][Full Text] [Related]  

  • 35. FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia.
    Macdougall IC; Bock AH; Carrera F; Eckardt KU; Gaillard C; Van Wyck D; Roubert B; Nolen JG; Roger SD;
    Nephrol Dial Transplant; 2014 Nov; 29(11):2075-84. PubMed ID: 24891437
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intravenous Iron Isomaltoside 1000 Reduces Postoperative Anemia in Patients Undergoing Elective Urologic Surgery and Those with Urosepsis.
    Goh HJ; Lee KS; Kim TH; Kim KN; Lim HJ; Kim KS; Yang WJ; Jo JK
    Drug Des Devel Ther; 2020; 14():5679-5687. PubMed ID: 33380788
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Conversion of haemodialysis patients from iron sucrose to iron isomaltoside: a real-world experience.
    Jesus-Silva JA; Lamplugh A; Dhada S; Burton JO; Bhandari S
    BMC Nephrol; 2020 Jun; 21(1):212. PubMed ID: 32493240
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ferric Carboxymaltose Versus Ferrous Fumarate in Anemic Children with Inflammatory Bowel Disease: The POPEYE Randomized Controlled Clinical Trial.
    Bevers N; Van de Vijver E; Aliu A; Rezazadeh Ardabili A; Rosias P; Stapelbroek J; Bertrams Maartens IA; van de Feen C; Escher H; Oudshoorn A; Teklenburg S; Vande Velde S; Winkens B; Raijmakers M; Vreugdenhil A; Pierik MJ; van Rheenen PF
    J Pediatr; 2023 May; 256():113-119.e4. PubMed ID: 36563900
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intravenous iron sucrose versus oral iron supplementation for the treatment of iron deficiency anemia in patients with inflammatory bowel disease--a randomized, controlled, open-label, multicenter study.
    Schröder O; Mickisch O; Seidler U; de Weerth A; Dignass AU; Herfarth H; Reinshagen M; Schreiber S; Junge U; Schrott M; Stein J
    Am J Gastroenterol; 2005 Nov; 100(11):2503-9. PubMed ID: 16279906
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systematic review with network meta-analysis: comparative efficacy and tolerability of different intravenous iron formulations for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease.
    Aksan A; Işık H; Radeke HH; Dignass A; Stein J
    Aliment Pharmacol Ther; 2017 May; 45(10):1303-1318. PubMed ID: 28326596
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.